We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| BTG | BGC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 387.50 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 387.50 | 387.50 |
| Top Posts |
|---|
Posted at 12/6/2012 12:09 by betman for info -i noticed that there are now two groups of threads going under epics bgc and btg |
Posted at 29/5/2012 17:00 by bargainbob BTG plc - Notification of change of TIDMBTG plc (the Company) would like to advise that with effect from 30 May 2012 the Company's TIDM will change from BGC to BTG. - ends - |
Posted at 25/5/2012 12:02 by aquila2001 RNSTIDMBGC BTG PLC 25 May 2012 BTG to present at the Jefferies Global Healthcare Conference London, UK, 25 May 2012: BTG plc (LSE: BGC), the specialist healthcare company, today announces that Louise Makin, CEO, will be presenting at the Jefferies Global Healthcare Conference in New York, US on Thursday, 7 June at 9.00am EDT (New York time), 2.00pm BST (London time). The presentation will be uploaded to the BTG's website in the Investor/Results and Presentations area shortly after the presentation has concluded to ensure access for anyone unable to attend in person. |
Posted at 26/4/2012 22:00 by cumnor No idea BB. Now the trials are out of the way I presume the main clinical expense is as well, unless the FDA get thick. After that it's pure marketing which may not be that expensive (compared to for ex another BP drug or CVS tablet in general practice where the market is saturated and so serious marketing is required). I think the medical (not consumer) market for Varisolve will be narrow-vascular surgeons, maybe radiologists, expense concious HMOs and Insurers and then slowly raising awareness with some consumer marketing (in the US) and primary care. It is somewhat unique and a first (regulated) of it's kind so the important guys will already be aware of it. I believe you are sometimes better cutting a deal with the big guys with huge marketing clout, contacts and know-how. Because it is virtually past P3 any deal would have to be on excellent terms for BGC. Don't know how big or good BTG's US team is-maybe it can do alone. imo |
Posted at 26/4/2012 21:40 by bargainbob CumnorEven a partial sale could happen. Re Varisolve how much will BGC need to raise in order to do a proper Launch. 50 million ? |
Posted at 26/4/2012 08:30 by cumnor Think your pension is perfectly safe more than and hopefully adequate) with AZN, fhm. I am impressed that BGC did'nt feel the need to RNS the excellent MS tx trial news, given that it will most likely be a significant earner for them. I know their share is small but this will imo be a big, big product. Says something about the stature of the company. imo dyor |
Posted at 26/4/2012 07:54 by cumnor Not just at AZN, AM. AZN's statement just confirms need for many big pharmas to act quickly and I expect a move on BGC in no time. This company's product and pipeline offering are even now worth at least three times the value the London market attributes to them. I am not ramping. aimo dyor |
Posted at 22/4/2012 22:24 by cumnor Agree, more.. Would'nt surprise me if GSK grabbed BGC from under the nose of AZN which has been slow off the mark of late on many fronts. I expect this to go within 6 months, given the pipeline shortage several big Pharmas are facing. In any case they are no longer interested in R&D-too expensive, problematic and unpredictable given time frames-even in the rare event they do find a BB. AZN out of luck of late. Far easier to buy small Pharma like BGC with several products on sale and a very decent pipeline. This could even now with a small battle go for 5bln+ given the income stream it's portfolio and pipeline might generate under big Pharma with their marketing muscle and spend. That's how they work. imo |
Posted at 09/3/2012 23:18 by cumnor Zytiga not just a bonus. Cpuld be 3-4bln bb, at 3-5% to bGC very significant. I have discounted the Sepsis drug when I bought bGC as these usally fail, and given the hx it is likely to. If....it suceeds BGC will quintuple. There is no other drug and the market is big. But BTG has more than enough without to fly.imo |
Posted at 08/3/2012 18:25 by toffeeman4 Be very surprised if divi was paid for current year. Think company will preserve cash for continuing expansion. Dividends or the prospect of future dividends ultimately drive share prices and support them, and just think that 10p per share divi would mean the shares yielding close to 3% at todays price. My view is we will start seeing divis when Varisolve starts to produce cash.The news today could well produce royalties of £40m+ in total for Arbiraterone. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
